Literature DB >> 16177957

Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis.

Yoshinao Oda1, Hidetaka Yamamoto, Tomonari Takahira, Chikashi Kobayashi, Kenichi Kawaguchi, Naomi Tateishi, Yoko Nozuka, Sadafumi Tamiya, Kazuhiro Tanaka, Shuichi Matsuda, Ryohei Yokoyama, Yukihide Iwamoto, Masazumi Tsuneyoshi.   

Abstract

In myxoid/round cell liposarcoma (MLS/RCLS), the presence of a round cell (RC) component has been reported to correlate with a worse prognosis for the patients. However, little is known about the molecular genetic differences between conventional myxoid (MX) components and RC components in this tumour. The aim of this study was to investigate the possible implications of molecular alterations of G1 to S-phase check-point genes, especially in the RC component. We evaluated the immunohistochemical expression of p53, MDM2, p14 and p16 protein and assessed proliferative activities using MIB-1 in 29 RC components and 81 MX components from 90 cases. Mutation of the p53 gene, amplification of the MDM2 gene, homozygous deletion, methylation status and mutation of the p16(INK4a)/p14(ARF) genes were also investigated, using concordant paraffin-embedded and frozen material. The data were analysed together with clinicopathological factors to assess their prognostic implications in MLS/RCLS. Immunohistochemically, the over-expression of p53 protein (p = 0.01366) and the reduced expression of p14 (p < 0.0001) and p16 (p < 0.0001) proteins were significantly more frequently observed in RC components than in MX components. Reduced expression of p14 protein correlated significantly with hypermethylation of the p14(ARF) gene promoter (p = 0.0176) and over-expression of p53 protein (p = 0.00837). By univariate analysis, reduced expression of p14 and p53 missense mutation were found to reduce the rate of survival significantly (p < 0.05). Multivariate analysis, including clinicopathological factors, revealed that tumour site (p = 0.0251), the presence of an RC component (p = 0.0113), high MIB-1 labelling index (p = 0.0005) and p53 missense mutation (p = 0.0036) were adverse prognostic factors. In MLS/RCLS, reduction of p14 protein expression and p53 mutation were related to poor prognosis. Accordingly, the p14(ARF)/p53 pathway may contribute to the presence of an RC component and malignant progression in this tumour. Copyright 2005 Pathological Society of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16177957     DOI: 10.1002/path.1848

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  20 in total

Review 1.  Modeling sarcomagenesis using multipotent mesenchymal stem cells.

Authors:  Rene Rodriguez; Ruth Rubio; Pablo Menendez
Journal:  Cell Res       Date:  2011-09-20       Impact factor: 25.617

2.  Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation.

Authors:  Marieke A de Graaff; Jamie S E Yu; Hannah C Beird; Davis R Ingram; Theresa Nguyen; Jeffrey Juehui Liu; Svetlana Bolshakov; Károly Szuhai; Pierre Åman; Keila E Torres; Dina Lev; Torsten O Nielsen; Judith V M G Bovée; Alexander J Lazar; Neeta Somaiah
Journal:  Lab Invest       Date:  2016-06-06       Impact factor: 5.662

3.  ARF suppresses hepatic vascular neoplasia in a carcinogen-exposed murine model.

Authors:  Stephanie E Busch; Kay E Gurley; Russell D Moser; Christopher J Kemp
Journal:  J Pathol       Date:  2012-05-08       Impact factor: 7.996

4.  PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma.

Authors:  Elizabeth Charytonowicz; Melissa Terry; Katherine Coakley; Leonid Telis; Fabrizio Remotti; Carlos Cordon-Cardo; Robert N Taub; Igor Matushansky
Journal:  J Clin Invest       Date:  2012-02-01       Impact factor: 14.808

5.  Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread?

Authors:  Elisabetta Pennacchioli; Giulio Tosti; Massimo Barberis; Tommaso M De Pas; Francesco Verrecchia; Claudia Menicanti; Alessandro Testori; Giovanni Mazzarol
Journal:  Clin Exp Metastasis       Date:  2012-06-15       Impact factor: 5.150

6.  p14(ARF) methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma.

Authors:  Radoslav Davidović; Jelena Sopta; Vesna Mandušić; Milena Krajnović; Maja Stanojević; Goran Tulić; Bogomir Dimitrijević
Journal:  Med Oncol       Date:  2013-08-06       Impact factor: 3.064

7.  Biological characterization of soft tissue sarcomas.

Authors:  Takuma Hayashi; Akiko Horiuchi; Kenji Sano; Yae Kanai; Nobuo Yaegashi; Hiroyuki Aburatani; Ikuo Konishi
Journal:  Ann Transl Med       Date:  2015-12

Review 8.  Therapeutic targets in the ARF tumor suppressor pathway.

Authors:  Anthony J Saporita; Leonard B Maggi; Anthony J Apicelli; Jason D Weber
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

9.  Two distinct pathways of p16 gene inactivation in gallbladder cancer.

Authors:  Hiroyuki Tadokoro; Takako Shigihara; Tomomi Ikeda; Masaru Takase; Masafumi Suyama
Journal:  World J Gastroenterol       Date:  2007-12-21       Impact factor: 5.742

10.  Mouse models of sarcomas: critical tools in our understanding of the pathobiology.

Authors:  Sean M Post
Journal:  Clin Sarcoma Res       Date:  2012-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.